Full Press Release Details
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine.
ALT
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
Key Takeaway: Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight